August J. Moretti

Insider Reports History

Reporting-owner location: Mountain View, CA
Latest reporting-owner signature: /s/ Anthony Baldor, Attorney-in-fact
Source: Latest parsed Forms 3/4/5 signature
Transaction source note: Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for August J. Moretti

Form 4 holding Chief Financial Officer

4D Molecular Therapeutics, Inc.

Security class: Common Stock
Shares / value: 11,045
Estimated value: $203,315
Report date: 15 May 2023
Price: $18.41
Ownership: Direct

Form 4 holding Director

Cibus, Inc.

Security class: Class A Common Stock
Shares / value: 0
Estimated value: $0
Report date: 18 Nov 2024
Price: $4.32
Ownership: Direct

Form 4 holding Chief Financial Officer

4D Molecular Therapeutics, Inc.

Security class: Stock Option (Right to Buy)
Shares / value: 217,060
Estimated value
Report date: 15 May 2023
Price
Ownership: Direct
Underlying class: Common Stock
Underlying amount

Form 4 holding Director

Cibus, Inc.

Security class: Stock Option (Right-to-Buy)
Shares / value: 77,586
Estimated value
Report date: 02 Jun 2026
Price
Ownership: Direct
Underlying class: Class A Common Stock
Underlying amount

Form 4 holding Director

Vivani Medical, Inc.

Security class: Non-Qualified Stock Option (right to buy)
Shares / value: 36,000
Estimated value
Report date: 24 Jun 2026
Price
Ownership: Direct
Underlying class: Common Stock
Underlying amount

Insider Reports Filed by August J. Moretti

4 VANI

Vivani Medical, Inc.

Report period: 24 Jun 2026
Transactions: 1
Transaction value: $0
Accepted by SEC: 26 Jun 2026, 14:27
Role: Director
Next action: Open filing details

3 VANI

Vivani Medical, Inc.

Report period: 24 Jun 2026
Transactions: 0
Transaction value: $0
Accepted by SEC: 26 Jun 2026, 14:21
Role: Director
Next action: Open filing details

4 CBUS

Cibus, Inc.

Report period: 02 Jun 2026
Transactions: 1
Transaction value: $0
Accepted by SEC: 04 Jun 2026, 17:47
Role: Director
Next action: Open filing details

4 CBUS

Cibus, Inc.

Report period: 22 May 2025
Transactions: 1
Transaction value: $0
Accepted by SEC: 27 May 2025, 15:22
Role: Director
Next action: Open filing details

4 CBUS

Cibus, Inc.

Report period: 20 Nov 2024
Transactions: 1
Transaction value: $0
Accepted by SEC: 25 Nov 2024, 16:42
Role: Director
Next action: Open filing details

3 CBUS

Cibus, Inc.

Report period: 18 Nov 2024
Transactions: 0
Transaction value: $0
Accepted by SEC: 25 Nov 2024, 16:36
Role: Director
Next action: Open filing details

4 FDMT

4D Molecular Therapeutics, Inc.

Report period: 15 May 2023
Transactions: 2
Transaction value: +$28,230
Accepted by SEC: 16 May 2023, 20:52
Role: Chief Financial Officer
Next action: Open filing details

4 FDMT

4D Molecular Therapeutics, Inc.

Report period: 10 Feb 2023
Transactions: 1
Transaction value: $0
Accepted by SEC: 14 Feb 2023, 19:26
Role: Chief Financial Officer
Next action: Open filing details

4 FDMT

4D Molecular Therapeutics, Inc.

Report period: 21 Dec 2022
Transactions: 2
Transaction value: +$28,230
Accepted by SEC: 22 Dec 2022, 17:51
Role: Chief Financial Officer
Next action: Open filing details

4 FDMT

4D Molecular Therapeutics, Inc.

Report period: 01 Sep 2022
Transactions: 1
Transaction value: $0
Accepted by SEC: 06 Sep 2022, 20:41
Role: Chief Financial Officer
Next action: Open filing details

4 FDMT

4D Molecular Therapeutics Inc.

Report period: 01 Feb 2022
Transactions: 1
Transaction value: $0
Accepted by SEC: 03 Feb 2022, 16:43
Role: Chief Financial Officer
Next action: Open filing details

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .